Skip to main content
Premium Trial:

Request an Annual Quote

TissueInformatics Pairs With Ohio Startup For Obesity, Diabetes Research

NEW YORK, April 26-DiAthegen and TissueInformatics said today that they would be working together to find new drug targets and diagnostics for obesity and type II diabetes.

 

The research agreement, slated to last five years, seeks to correlate gene expression changes to histological changes during the initiation and progression of type II diabetes. The studies will include both animal and human tissues.

 

DiAthegen will supply animal modeling, molecular biology and transgenic animal services to the cooperative effort.

 

TissueInformatics will provide automated tissue imaging, tissue analysis and gene expression capabilities.

 

The companies did not disclose financial details of the arrangement.

 

DiAthegen, an Athens, Ohio startup, seeks to develop new diagnostics and therapeutics for obesity, diabetes and hyperinsulinemea through genomic and animal models.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.